Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7241Neoplasms 4538Prostatic Neoplasms 3489Colorectal Neoplasms 2939Carcinoma, Non-Small-Cell Lung 2829Lung Neoplasms 2546Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1873Multiple Myeloma 1810Carcinoma, Hepatocellular 1732Neoplasm Metastasis 1585Stomach Neoplasms 1501Lymphoma 1456Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1434Brain Neoplasms 1370Melanoma 1346Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1254Colonic Neoplasms 1204Glioblastoma 1137Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1065Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × BRCA1 Mutation × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

NCT05420064 2025-11-12

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Memorial Sloan Kettering Cancer Center

Phase NA Recruiting
1,000 enrolled

BRCA1 Mutation

NCT01630226 2012-07-12

Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland

Pomeranian Medical University Szczecin

Phase 2 Unknown
100 enrolled
Breast

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡